Sarah Cannon Research Institute | Strategic Alliance Partners

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses data with talazoparib in breast cancer.

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the impact of the CARMENA trial results in renal cell carcinoma.

Suman Kambhampati, MD, discusses some of the latest developments in the treatment of patients with relapsed/refractory multiple myeloma.

Denise A. Yardley, MD, weighs in on the recent data reported in breast cancer.

Jesus G. Berdeja, MD, director of Myeloma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of frontline daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of the chimeric antigen receptor T-cell therapy tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma.

Carlos R. Bachier, MD, director, blood and marrow transplant research, Sarah Cannon Research Institute, discusses toxicities associated with stem cell transplant.

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses ongoing trials in hematologic malignancies.

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses combinations under investigation in acute leukemia.

Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of brentuximab vedotin (Adcetris) combined with Adriamycin, vinblastine, and dacarbazine (AVD) as a frontline treatment for patients with advanced classical Hodgkin lymphoma.

Carlos R. Bachier, MD, program director of Sarah Cannon Center for Blood Cancer, Sarah Cannon Research Institute, discusses the relationship between chimeric antigen receptor (CAR) T-cell therapy and stem cell transplant.

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the rationale behind the design of PACIFIC, a trial that investigated the use of durvalumab (Imfinzi) in patients with locally advanced, unresectable stage III lung cancer.

Ian W. Flinn, MD, PhD, discusses the impact of CAR T-cell therapy on the field of lymphoma and highlighted emerging options for the treatment of patients with MCL.

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the current landscape of myelodysplastic syndromes (MDS).

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, reflects on some of the most pivotal FDA approvals in acute leukemia in the past year.

David R. Spigel, MD, discusses the status of immunotherapy in locally advanced NSCLC and highlights recent milestones.

Jesus Berdeja, MD, provides an update on practice-changing data for the treatment of patients with multiple myeloma.

Carlos R. Bachier, MD, discusses the evolution of stem cell transplantation as a treatment for patients with hematologic malignancies.

Suman Kambhampati, MD, discusses available treatments for MDS and ongoing clinical trials investigating targeted treatments in myeloid malignancies.

Ian W. Flinn, MD, discusses ongoing advances with emerging combination regimens in chronic lymphocytic leukemia.

Jesus Berdeja, MD, reflects on pivotal studies in multiple myeloma and discussed potential advancements in the upcoming year.

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses the future of treatment for patients with myeloma.

Carlos R. Bachier, MD, director, blood and marrow transplant research, Sarah Cannon Research Institute, discusses the advancement of supportive care in hematologic malignancies.

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Cancer Institute, discusses the impact of single-agent venetoclax (Venclexta) in patients with myeloid malignancies.

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses combinations in light of newly FDA-approved agents in acute myeloid leukemia (AML).

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the toxicities associated with the combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL).

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses response to the chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with multiple myeloma.

Jesus Berdeja, MD, discusses ongoing research with bb2121 in patients with relapsed/refractory myeloma.

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses next steps with venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses a study of bb2121, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy.